SRC as a potential therapeutic target in solid tumor oncology.
Gallick
Gary E
GE
University of Texas M. D. Anderson Cancer Center, TX, USA.
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000556:secondary; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D066246:ErbB Receptors / Q000502:physiology; D016391:Genes, src; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D010010:Osteoclasts / Q000187:drug effects; D018579:Patient Selection; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors; D016392:Proto-Oncogene Proteins pp60(c-src)